[1] |
World Health Organization. Global tuberculosis report 2020. Geneva: World Health Organization, 2020.
|
[2] |
Diacon AH, Pym A, Grobusch M, et al. The diarylquinoline TMC 207 for multidrug-resistant tuberculosis. N Engl J Med, 2009, 360(23): 2397-2405. doi: 10.1056/NEJMoa0808427.
doi: 10.1056/NEJMoa0808427
URL
|
[3] |
Diacon AH, Pyre A, Grobusch MP, et al. Multidrug-resis-tant tuberculosis and culture conversion with bedaquiline. N Engl J Med, 2014, 371(8): 723-732. doi: 10.1056/NEJMoal313865.
doi: 10.1056/NEJMoal313865
URL
|
[4] |
Gao M, Gao J, Xie L, et al. Early outcome and safety of bedaquiline-containing regimens for treatment of MDR mad XDR TB in China: a multicentre study. Clin Microbiol Infect, 2021, 27 (4): 597-602. doi: 10.1016/j.cmi.2020.06.004.
doi: 10.1016/j.cmi.2020.06.004
URL
|
[5] |
World Health Organization. Report of the guideline development group meeting on the use of bedaquiline in the treatment of mulltidrug resistant tuberculosis: a review of available evidence(2016). Geneva: World Health Organization, 2016.
|
[6] |
World Health Organization. Meeting report of the WHO expert consultation on the definition of extensively drug-resis-tant tuberculosis, 27-29 October 2020. Geneva: World Health Organization, 2021.
|
[7] |
中国防痨协会. 耐药结核病化学治疗指南(2019年简版). 中国防痨杂志, 2019, 41(10): 1025-1073. doi: 10.3969/j.issn.10006621.2019.10.001.
doi: 10.3969/j.issn.10006621.2019.10.001
|
[8] |
中国防痨协会. 耐药结核病化学治疗指南(2015). 中国防痨杂志, 2015, 37(5): 421-469. doi: 10.3969/J.issn.10006521.2015.05.001.
doi: 10.3969/J.issn.10006521.2015.05.001
|
[9] |
World Health Organization. WHO consolidated guidelines on Drug-resistant tuberculosis treatment. Geneva: World Health Organization, 2019.
|
[10] |
World Health Organization. The use of bedaquiline in the treatment of multidrug-resistant tuberculosis: interim policy guidance. Geneva: World Health Organization, 2013.
|
[11] |
U.S. Department of Health and Human Services. Common terminology criteria for adverse events (CTCAE)[EB/OL].[2021-01-21]. https://ctep.cancer.Gov/protoco1development/electronic_applications/docs/CTCAE_v5_Quick_Reference_5x7.pdf.
|
[12] |
Pyre AS, Diacon AH, Tang SJ, et al. Bedaquiline in the treatnlent of multidrug-and extensively drug-resistant tuberculosis. Eur Respir J, 2016, 47(2): 564-574. doi: 10.1183/13993003.007242015.
doi: 10.1183/13993003.007242015
URL
|
[13] |
Haagsma AC, Podasca I, Koul A, et al. Probing the interaction of the diarylquinoline TMC207 with its target mycobacterial ATP synthase. PLoS One, 2011, 6(8): e23575. doi: 10.1371/10urnal.pone.0023575.
doi: 10.1371/10urnal.pone.0023575
|
[14] |
时正雨, 吴桂辉, 黄涛, 等. 含贝达喹啉方案治疗耐多药/广泛耐药结核病的24周单组观察性研究. 中国防痨杂志, 2021, 43 (5): 487-494. doi: 10.3969/j.issn.1000-6621.2021.05.014.
doi: 10.3969/j.issn.1000-6621.2021.05.014
|
[15] |
Borisov SE, Dheda K, Enwerem M, et al. Effectiveness and safety of hedaquiline-containing regimens in the treatment of MDR and XDR TB: a multicentre study. Eur Respir J, 2017, 49(5): 1700387. doi: 10.1183/13993003.00387-2017.
doi: 10.1183/13993003.00387-2017
|
[16] |
Postema PG, Wilde AA. The measurement of the QT interval. CLlrr Cardiol Rev, 2014, 10(3): 287294. doi: 10.2174/1573403x10666140514103612.
doi: 10.2174/1573403x10666140514103612
|
[17] |
中华医学会结核病学分会, 抗结核新药贝达喹啉临床应用专家共识编写组. 抗结核新药贝达喹啉临床应用专家共识. 中华结核和呼吸杂志, 2021, 44(2): 81-87. doi: 10.3760/cma.I.issn.1001-0939.2018.06.005.
doi: 10.3760/cma.I.issn.1001-0939.2018.06.005
|
[18] |
Mbuagbaw I, Guglielmetti I, Hewison C, et al. Outcomes of Bedaquiline Treatment in Patients with Multidrug-Resistant Tuberculosis. Emerg Infect Dis, 2019, 25(5): 936-943. doi: 10.3201/eid2505.181823.
doi: 10.3201/eid2505.181823
URL
|
[19] |
Guglielmetti L, Le Du D, Jachym M, et al. Compassionate use of bedaquiline for the treatment of multidrug resistant and extensively drug resistant tuberculosis: interim analysis of a French cohort. C1in Infect Dis, 2015, 60(2): 188-194. doi: 10.1093/cid/ciu786.
doi: 10.1093/cid/ciu786
|
[20] |
谢莉, 高静韬, 马丽萍 等. 含贝达喹啉方案治疗耐多药肺结核对患者心电图QT间期的影响. 中国防痨杂志, 2020, 42(7): 687-694. doi: 10.3969j.issn.1000-6621.2020.07.009.
doi: 10.3969j.issn.1000-6621.2020.07.009
|
[21] |
Jones J, Mudaly V, Voget J, et al. Adverse drug reactions in South African patients receiving bedaquiline-containing tuberculosis treatment: an evaluation of spontaneously reported cases. BMC Infect Dis, 2019, 19(1): 544. doi: 10.1186/s128790194197-7.
doi: 10.1186/s128790194197-7
|
[22] |
Lachenal N, Hewison C, Mitnick C, et al. Setting up pharma covigilance based on available end TB Project data for bedaquiline. Int J Tuberc Lung Dis, 2020, 24(10): 1087-1094. doi: 10.5588/ijtld.20.0115.
doi: 10.5588/ijtld.20.0115
pmid: 33126944
|
[23] |
Hu M, Zheng C, Gao F. Use of bedaquiline and delamanid in diabetes patients: clinical and pharmacological considerations. Drug Des Devel Ther, 2016, 10: 3983-3994. doi: 10.2147/DDDT.S121630.
doi: 10.2147/DDDT.S121630
URL
|
[24] |
Chahine EB, Karaoui LR, Mansour H. Bedaquiline: a novel diarylquinoline for multidrug-resistant tuberculosis. Ann Pharmacother, 2014, 48(1): 107-115. doi: 10.1177/1060028013504087.
doi: 10.1177/1060028013504087
pmid: 24259600
|